Skip to content

AMLX AMYLYX PHARMACEUTICALS INC

Follow

COM (common), issuer CIK 1658551

Filings received so far for Q3 2026: 6 13F filers report a position in AMLX shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.

13D and 13G filers

No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.

Insider trades

The latest Form 4 transactions, non-derivative.
OwnerDateSharesPriceFiling
MILNE GEORGE M JRdirector2026-10-05-30,000 S$27.6968Form 4

13F holders, Q3 2026

Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.

HolderSharesValue% of portfolioChangeSource
Valeo Financial Advisors, LLC10,074$293K0.01%+2913F-HRTimeline
GAMMA Investing LLC1,139$33.1K<0.01%+70613F-HRTimeline
EASTERN BANK721$21K<0.01%013F-HRTimeline
MassMutual Private Wealth & Trust, FSB354$10.3K<0.01%-6613F-HRTimeline
Farther Finance Advisors, LLC316$9.2K<0.01%+5713F-HRTimeline
CoreCap Advisors, LLC9$262<0.01%new13F-HRTimeline

Events

  • MILNE GEORGE M JR sold 30,000 AMLX shares on 2026-10-05, Form 4 filed 2026-10-07. 0001193125-26-416950

    Accepted , ingested